Navigation Links
Cord blood cell transplantation provides improvement for severely brain-injured child

Tampa, Fla. (Dec. 22, 2010) In three monthly injections, researchers transplanted neurally-committed, autologous cord blood derived cells tagged with iron oxide nanoparticles (SPIO) into the lateral cerebral ventricle of a 16-month old child with severe global hypoxic ischemic brain injury. The study, published in the current issue of Cell Medicine 1(2) and now freely available online at

found through MRI tracking that the primary injected and tagged cells persisted in that brain hemisphere for more than four months. By six months, the severely impaired child showed some slight improvement over a former vegetative state.

"Hypoxic-ischemic encephalopathy remains one of the most devastating conditions in children, resulting in brain atrophy and persistent functional neurological impairment," said Dr. Krystyna Domanska-Janik, corresponding author.

According to Dr. Domanska-Janik, they transplanted cord blood neural cells by repeated injection into lateral cerebral ventricle as the method appeared to be superior to intravascular injections because there would be a more "local modulating outcome."

"The capacity of cells to home to damaged sites in the central nervous system is crucial," said Dr. Domanska-Janik. "Our study found that transplantation of patient self-donor (autologous), neurally-committed cord blood cells is feasible, well tolerated, and safe."

Once more, the transplanted cells were easily assessed by MRI for four months.

"Despite signs of neurological improvement noticed by the parents and neurologists after cell transplantation, this one case does not allow us to predict the true efficacy of such a treatment and further studies are needed," she added.

The research team did suggest that six months post-transplantation, the child's diagnosis of a 'vegetative state' was no longer justified as the boy began responding to his mother's voice by smiling and a 50 percent reduction in his rate of seizures was achieved.

According to Dr. Paul Sanberg, executive director of the Center of Excellence for Aging and Brain Repair at the University of South Florida, and executive editor of Cell Medicine, this case report is potentially important.

"This first step in the use of autologous stem cells as a treatment for neonatal ischemic brain repair in the clinic provides a guardedly optimistic report for future studies," said Dr. Sanberg. "Of course, further and more comprehensive studies, with a larger patient population, are required to confirm its potential efficacy."


Contact: David Eve
Cell Transplantation Center of Excellence for Aging and Brain Repair

Related biology news :

1. Malaria-infected cells stiffen, block blood flow
2. Firefly protein lights pathway to improved detection of blood clots
3. CCNY professor gets grant to develop artificial blood
4. Scientists discover new mechanism for controlling blood sugar level
5. HIV drugs interfere with blood sugar, lead to insulin resistance
6. The lifeblood of leaves: Vein networks control plant patterns
7. Nanoengineers aim to grow tissues with functional blood vessels
8. McMaster scientists turn skin into blood
9. UC Riverside cell biologist to investigate how malaria parasite multiplies in red blood cells
10. X-ray crystallography reveals structure of precursor to blood-clotting protein
11. Listeria clever at finding its way into bloodstream, causing sickness
Post Your Comments:
(Date:5/9/2016)... , UAE, May 9, 2016 ... when it comes to expanding freedom for high net ... Even in today,s globally connected world, there is ... conferencing system could ever duplicate sealing your deal with ... obtaining second passports by taking advantage of citizenship via ...
(Date:4/26/2016)... and LONDON , April 26, ... of EdgeVerve Systems, a product subsidiary of Infosys ... announced a partnership to integrate the Onegini mobile ...      (Logo: ) ... customers enhanced security to access and transact across ...
(Date:4/15/2016)... Research and Markets has announced ... 2016-2020,"  report to their offering.  , ... global gait biometrics market is expected to grow ... 2016-2020. Gait analysis generates multiple variables ... to compute factors that are not or cannot ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in ... Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio ... practical tips, tools, and strategies for clinical researchers. , “The landscape of how ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... ... 2016 , ... Charm Sciences, Inc. is pleased to announce ... Research Institute approval 061601. , “This is another AOAC-RI approval of the Peel ... President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably to ...
Breaking Biology Technology: